%PDF-1.4
%
51 0 obj
<>
endobj
48 0 obj
<>
endobj
116 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-05T16:09:27Z
2021-09-09T01:47:20-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2021-09-09T01:47:20-07:00
application/pdf
Heather
2002-873.march
uuid:e1818705-1dd1-11b2-0a00-6209278d5b00
uuid:e1818707-1dd1-11b2-0a00-1e0000000000
endstream
endobj
37 0 obj
<>
endobj
38 0 obj
<>
endobj
52 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
22 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 31 0 R/Type/Page>>
endobj
130 0 obj
[134 0 R]
endobj
131 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.2368 Tw 10 0 0 10 54 398.1616 Tm
(Clinical followup studies in patients with early signs or)Tj
0.0184 Tw 0 -1.2 TD
(symptoms of the disease could verify whether anti-)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.5 (\002)]TJ
/T1_1 1 Tf
-0.0002 Tc [0.1 (-fodrin)]TJ
-0.00011 Tc 0.0914 Tw T*
(antibodies should be considered a predictive marker of SS)Tj
0.0193 Tc 0.35561 Tw T*
(and perhaps of other chronic autoimmune rheumatic)Tj
-0.00011 Tc 0 Tw T*
(diseases. )Tj
/T1_3 1 Tf
0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_1 1 Tf
0.1476 Tw 8 0 0 8 54 316.1616 Tm
(The authors thank L. Inverso for her assistance in preparing this manu-)Tj
0 Tw 0 -1.25 TD
(script.)Tj
/T1_3 1 Tf
10 0 0 10 54 282.1616 Tm
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61.6 272.1616 Tm
[(1.)-675.1 (Anaya JM, )17.7 (T)69.9 (alal N. Sj\232gren\325)54.8 (s syndrome and connective tissue)]TJ
1.45 -1.25 Td
(diseases associated with other immunologic disorders. In: Koopman)Tj
T*
[(WJ, editor)54.8 (. )54.7 (Arthritis and allied conditions. Baltimore: )17.6 (W)39.8 (illiams &)]TJ
T*
[(W)39.9 (ilkins; 1997:1561-80.)]TJ
-1.45 -1.25 Td
[(2.)-675.1 (Haneji N, Nakamura )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (akio K, et al. Identification of )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 23.8745 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin as)]TJ
-22.4244 -1.25 Td
[(a candidate autoantigen in primary Sj\232gren\325)54.8 (s syndrome. Science)]TJ
0 Tc 0 Tw T*
(1997;276:604-7.)Tj
-0.00011 Tc 0.02499 Tw -1.45 -1.25 Td
[(3.)-675.1 (Miyagawa S, )36.8 (Y)99.8 (anagi K, )36.8 (Y)99.8 (oshioka )54.8 (A, Kidoguchi K, Shirai )17.7 (T)74 (,)]TJ
1.45 -1.25 Td
[(Hayashi )36.8 (Y)128.9 (. Neonatal lupus erythematosus: maternal IgG antibodies)]TJ
T*
(bind to a recombinant NH)Tj
0 Tc 0 Tw 5.2 0 0 5.2 157.5293 179.5216 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 160.1293 182.1616 Tm
(-terminal fusion protein encoded by)Tj
0 Tw -10.8662 -1.25 Td
(human )Tj
/T1_2 1 Tf
0 Tc 2.9967 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin cDNA. J Invest Dermatol 1998;1)36.8 (1)36.8 (1:1)36.8 (189-92.)]TJ
28.5534 48.1085 Td
[(4.)-675.1 (W)79.9 (atanabe )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (suchida )17.7 (T)74 (, Kanda N, Mori K, Hayashi )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (amaki K.)]TJ
-0.0002 Tc 0 Tw 1.45 -1.25 Td
(Anti-)Tj
/T1_2 1 Tf
0 Tc [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin antibodies in Sj\232gren\325)54.8 (s syndrome and lupus )]TJ
T*
[(erythematosus. )54.8 (Arch Dermatol 1999;135:535-9. )]TJ
-1.45 -1.25 Td
[(5.)-675.1 (W)39.9 (itte )17.7 (T)74 (, Matthias )17.7 (T)74 (,)-0.1 ( )54.8 (Arnett FC, et al. IgA)-220.2 (and IgG autoantibodies)]TJ
0 Tw 1.45 -1.25 Td
(against )Tj
/T1_2 1 Tf
0 Tc 3.1073 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin as markers for Sj\232gren\325)54.8 (s syndrome. J Rheumatol)]TJ
0 Tc 0 Tw -3.1072 -1.25 Td
(2000;27:2617-20.)Tj
-0.00011 Tc 0.02499 Tw -1.45 -1.25 Td
[(6.)-675.1 (T)69.9 (akahashi K, )17.7 (T)69.9 (atsuzawa O, )36.8 (Y)99.8 (anagi K, Hayashi )36.8 (Y)128.9 (,)-0.1 ( )17.7 (T)69.9 (akahashi H.)]TJ
1.45 -1.25 Td
[(Alpha-fodrin auto-antibody in Sj\232gren\325)54.8 (s syndrome and other)]TJ
T*
(autoimmune diseases in childhood. Eur J Pediatr 2001;160:520-1.)Tj
-1.45 -1.25 Td
[(7.)-675.1 (Maeno N, )17.7 (T)69.9 (akei S, Imanaka H, et al. )54.8 (Anti-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 18.531 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin antibodies in)]TJ
-17.081 -1.25 Td
[(Sj\232gren\325)54.8 (s syndrome in children. J Rheumatol 2001;28:860-4.)]TJ
-1.45 -1.25 Td
[(8.)-675.1 (Kobayashi I, Kawamura N, Okano M, et al. )54.8 (Anti-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 21.3955 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc [0.2 (-fodrin )]TJ
0.02499 Tw -19.9456 -1.25 Td
(autoantibody is an early diagnostic marker for childhood primary)Tj
T*
[(Sj\232gren\325)54.8 (s syndrome. J Rheumatol 2001;28:363-5.)]TJ
-1.45 -1.25 Td
[(9.)-675.1 (V)59.8 (itali C, Bombardieri )17.7 (VC, Moutsopoulos HM, et al. Preliminary)]TJ
1.45 -1.25 Td
[(criteria for the classification of Sjogren\325)54.8 (s syndrome. Results of a)]TJ
T*
(prospective concerted action supported by the European)Tj
T*
[(Community)64.9 (. )54.8 (Arthritis Rheum 1993;36:340-7.)]TJ
-1.95 -1.25 Td
[(10.)-675.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
1.95 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -1.9131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-675.1 (Hochber)17.7 (g MC. Updating the )54.8 (American College of Rheumatology)]TJ
1.9131 -1.25 Td
(revised criteria for the classification of systemic lupus )Tj
T*
[(erythematosus [letter]. )54.8 (Arthritis Rheum 1997;40:1745.)]TJ
-1.95 -1.25 Td
[(12.)-675.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.95 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;3:315-24.)]TJ
-1.95 -1.25 Td
[(13.)-675.1 (Subcommittee for Scleroderma Criteria of the )54.8 (American)]TJ
1.95 -1.25 Td
[(Rheumatism )54.8 (Association Diagnostic and )17.7 (Therapeutic Criteria)]TJ
T*
(Committee. Preliminary criteria for the classification of systemic)Tj
T*
[(sclerosis \(scleroderma\). )54.8 (Arthritis Rheum 1980;23:581-90.)]TJ
-1.95 -1.25 Td
[(14.)-675.1 (Bohan )54.8 (A, Peter JB. Polymyositis and dermatomyositis. N Engl )]TJ
0 Tc 1.95 -1.25 Td
(J Med 1975;292:344-7, 403-7.)Tj
-0.00011 Tc -1.95 -1.25 Td
[(15.)-675.1 (Inoue H, )17.7 (T)69.9 (subota K, Ono M, et al. Possible involvement of )]TJ
0 Tw 1.95 -1.25 Td
[(EBV)91.7 (-mediated )]TJ
/T1_2 1 Tf
0 Tc 6.1808 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin cleavage for or)17.7 (gan-specific autoantigen in)]TJ
-6.1807 -1.25 Td
[(Sj\232gren\325)54.8 (s syndrome. J Immunol 2001;166:5801-9.)]TJ
-1.95 -1.25 Td
[(16.)-675.1 (T)69.9 (oda I. )54.8 (Autoantigens and Sj\232gren\325)54.8 (s syndrome. Cornea )]TJ
0 Tc 0 Tw 1.95 -1.25 Td
(2002;21:S13-6.)Tj
/T1_4 1 Tf
0.0627 Tw -35.4 45.5214 Td
[(T)91.9 (able 2. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.8563 0 Td
(The prevalence of anti-)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.06281 Tw [0.1 (-fodrin antibodies in childhood patients)]TJ
0.02499 Tw -3.8563 -1.25 Td
(and healthy controls.)Tj
0 -2.5 TD
[(Antibody Isotype)-3822 (T)69.9 (akahashi)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 172.8572 523.8404 Tm
(6)Tj
-0.00011 Tc 8 0 0 8 175.4572 521.2004 Tm
[(,)-2392.1 (Maeno)]TJ
0 Tc 5.2 0 0 5.2 218.8065 523.8404 Tm
(7)Tj
-0.00011 Tc 8 0 0 8 221.4064 521.2004 Tm
[(,)-2198.6 (Kobayashi)]TJ
0 Tc 5.2 0 0 5.2 275.2055 523.8404 Tm
(8)Tj
8 0 0 8 277.8054 521.2004 Tm
(,)Tj
-0.0002 Tc 0.02499 Tw -17.3115 -1.25 Td
[(T)69.8 (otal Ig \(%\))-2250.4 (IgG \(%\))-2972.2 (IgG \(%\))]TJ
-0.00011 Tc -10.6642 -2.5 Td
[(Primary SS)-6658.2 (3/3 \(100\))-2193.6 (1)36.8 (1/1)36.8 (1 \(100\))-2118.6 (7/7 \(100\))]TJ
0 -1.25 TD
[(Secondary SS)-7018.1 (\321)-4015.9 (4/4 \(100\))-2831.7 (2/4 \(50\))]TJ
T*
[(SLE)-9363.3 (5/6 \(83.3\))-2156.7 (2/16 \(12.5\))-2081.7 (1/7 \(14.3\))]TJ
T*
[(RA)-9752 (5/9 \(55.5\))-3890.9 (\321)-4440.9 (0/7 \(0\))]TJ
T*
[(DM)-11014.3 (\321)-5375.1 (\321)-4440.9 (0/7 \(0\))]TJ
T*
[(Healthy controls)-5104.4 (0/7 \(0\))-4515.9 (\321)-5300.1 (\321)]TJ
ET
0 0 0 1 K
0.5 w
53.6 535.2 m
294 535.2 l
54 504.8 m
294 504.8 l
54 433.6 m
295.2 433.6 l
S
BT
/T1_4 1 Tf
0 Tc 8 0 0 8 53.2 713.9004 Tm
[(T)91.9 (able 1. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.743 0 Td
(The prevalence of anti-)Tj
/T1_2 1 Tf
0 Tc 0 Tw [-0.1 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-fodrin antibodies in adult patients and healthy controls.)]TJ
-3.7429 -2.5 Td
[(Antibody Isotype)-8196.6 (Haneji)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 196.0621 696.5404 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 198.6621 693.9004 Tm
[(, Not)-2895 (Miyagawa)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 271.7809 696.5404 Tm
(3)Tj
-0.00011 Tc 8 0 0 8 274.3808 693.9004 Tm
[(,)-1669 (W)79.9 (atanabe)]TJ
0 Tc 5.2 0 0 5.2 321.0699 696.5404 Tm
(4)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 323.6699 693.9004 Tm
(, Not)Tj
8.11286 0 Td
[(W)39.9 (itte)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 406.0256 696.5404 Tm
(5)Tj
-0.00011 Tc 7.32159 Tw 8 0 0 8 408.6256 693.9004 Tm
(, Current )Tj
11.15052 0 Td
(Report,)Tj
-0.0002 Tc 0.02499 Tw -40.55332 -1.25 Td
[(Specified \(%\))-3161.6 (IgG \(%\))-2961.6 (Specified \(%\))-2914.1 (IgA)-220.3 (\(%\))-3674.7 (IgG \(%\))-2799.7 (IgA)-220.3 (\()0.1 (%\))-2374.7 (IgG \(%\) )]TJ
-0.00011 Tc -15.0254 -2.5 Td
(Primary SS)Tj
15.31603 0 Td
[(41/43 \(95.3\))-2793.6 (1)36.8 (1/1)36.8 (1 \(100\))-3093.6 (7/9 \(77.7\))-3231.7 (54/85 \(64\))-2381.7 (47/85 \(55.3\))-1131.7 (26/80 \(32.5\))-706.7 (17/80 \(21.2\))]TJ
-15.31603 -1.25 Td
(Secondary SS)Tj
15.81561 0 Td
(5/8 \(62.5\))Tj
9.08383 0 Td
(\321)Tj
6.04079 0 Td
[(9/15 \(60\))-3356.7 (13/22 \(59\))-2631.7 (9/22 \(40.9\))-3365.9 (\321)-4675.1 (\321)]TJ
-30.94023 -1.25 Td
(SLE)Tj
16.19098 0 Td
(0/21 \(0\))Tj
8.70904 0 Td
[(\321)-4915.9 (3/44 \(6.8\))-3731.7 (1/50 \(2\))-3756.7 (1/50 \(2\))-2381.7 (16/50 \(32\))-1456.7 (13/50 \(26\))]TJ
-24.90002 -1.25 Td
(RA)Tj
16.19079 0 Td
(0/14 \(0\))Tj
8.70905 0 Td
(\321)Tj
7.39999 0 Td
[(\321)-4590.9 (2/12 \(16.6\))-2506.7 (5/12 \(41.6\))-1381.7 (14/30 \(46.6\))-956.7 (4/30 \(13.3\))]TJ
-32.29982 -1.25 Td
(SSc)Tj
17.30008 0 Td
(\321)Tj
7.59999 0 Td
(\321)Tj
7.4 0 Td
(\321)Tj
7.32499 0 Td
(\321)Tj
6.97499 0 Td
[(\321)-3740.9 (4/20 \(20\))-1956.7 (3/20 \(15\))]TJ
-46.60005 -1.25 Td
(DM/PM)Tj
17.30007 0 Td
(\321)Tj
7.59999 0 Td
(\321)Tj
7.4 0 Td
(\321)Tj
7.32499 0 Td
(\321)Tj
6.975 0 Td
[(\321)-3740.9 (1/10 \(10\))-1956.7 (3/10 \(30\))]TJ
-46.60004 -1.25 Td
(Mothers of infants with NLE)Tj
17.29979 0 Td
(\321)Tj
6.24079 0 Td
(5/5 \(100\))Tj
8.75893 0 Td
(\321)Tj
7.325 0 Td
(\321)Tj
6.97498 0 Td
(\321)Tj
6.1 0 Td
[(\321)-4675.1 (\321)]TJ
-52.6995 -1.25 Td
(Healthy controls)Tj
16.19069 0 Td
[(0/15 \(0\))-4381.7 (0/10 \(0\))]TJ
16.10888 0 Td
[(\321)-4590.9 (1/160 \(0.6\))-2506.7 (3/160 \(1.8\))-1881.7 (1/60 \(1.6\))-1706.7 (5/60 \(8.3\))]TJ
-32.29957 -2.5 Td
(NLE: neonatal lupus erythematosus.)Tj
ET
56.2 707.5 m
556 707.5 l
53.2 677.5 m
556 677.5 l
52.8 585.9 m
556 585.9 l
S
1 w
54 54 m
558 54 l
S
BT
/T1_4 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Ruffatti, et al: )17.7 (Anti-alpha-fodrin in pSS)]TJ
0 Tc 0 Tw 61.4375 -0.0313 Td
(507)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-18.28697 0 Td
(Downloaded on September 9, 2021 from )Tj
ET
endstream
endobj
31 0 obj
<>stream
8;Z\7MfJkR#iu#8OPd%G=]c;W8^Q2Ubb=&[6ll^eVs5kCr%!o-4:]^3j7RfCce\&r
n+.c.Fm3bJk8'[^]:s4L$[I+r7)]0G0Blren5ZtZ]OIS-&J+9=0SN7-[^rtk0`;$o
!/sth3h`.A3-7``L%JESCi-#3pOj=+!]=O5)^8Q4Raf
4Ktc/6d7rF@!.N&U1l[\-1&+(0_]C:qST?n4Ts[8A^lY^%tKDY4:%J2.a12
R9jWI+bX1M"&I/\2jO@+a]c"]L@qM@O
V8GidJ@3pp6'F4>-!U@=_bJq/c?!\1GkuT~>
endstream
endobj
35 0 obj
[/Indexed/DeviceRGB 255 34 0 R]
endobj
34 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
98 0 obj
<>
endobj
58 0 obj
<>
endobj
66 0 obj
<>
endobj
72 0 obj
<>
endobj
55 0 obj
<>
endobj
107 0 obj
<>
endobj
121 0 obj
<>
endobj
54 0 obj
<>
endobj
92 0 obj
<>stream
HUmPSg7\4F.jѺFD*hu+*~-`)%H@B jGODT][gLm{nvc<9y}s^s`8{\jMXL^!*bN$>g.滰"7Zd*+ ǧ{UqU,BbpI^ak\S$LZȔrE\&,#yݫdD̾~1#U2ɌJ*%+v3L4SRgILrf:9)Ji4Y!(}?c3)̝861,`+),r
9=Hl9,PK%L!a<^'IY;]ͮhRۓ'?3R)1S =[<̞n[1U8L@vXYkXe.ؚQPzXYo1Qt'D| :ԆÕQ;@]&OZh
{/H1(6D4MxN
CFolCL:H?fy5QkWiMJZ2
FXp`tu'<;
.؟]PO7,Mc?.
x2nPoP_bZj1p6T֫ҪD8lrU<lEӢ$}:Kr:7`RFk(%د_ɹH)gh ;[O;AN@~eªRPkh54
UaËN$6``kGf嶂u\<ol ۷.Y_]SM;Fyml:w1Ǥq^fu-'ۻG\4\;?j{_<Pm۶m[(~ҽΓ]ͷzOKnL %`ǟWN|?VAgif>loNfð xv)lO/Yl<(q MJ}$N㹦S=ɛY^ШjpE5J$9hGPWHQ-4"o&5]1!%!製h H`